Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Evaluate Trial. Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment.

Published byOctavia Joseph Modified over 8 years ago

Similar presentations

Presentation on theme: "The Evaluate Trial. Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment."— Presentation transcript:

1 The Evaluate Trial

2 Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Reference Ando K, Ohtsu H, Arakawa Y, et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res. 2010;33:616–621.

3 Background Ando et al. identified the effects of mineralocorticoid receptor blockade in inhibiting ongoing renal damage in animal models of chronic kidney disease. The EVALUATE trial is designed to confirm these preliminary findings in clinical settings. This trial is expected to show whether a low dose of mineralocorticoid receptor antagonists can exert an anti-albuminuric effect in patients with chronic kidney disease.

4 Aim To evaluate the anti-albuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.

5 Methods

6 Results To be published.

7 Conclusion The trial is ongoing and is expected to show whether a low dose of mineralocorticoid receptor antagonists can exert an anti-albuminuric effect in patients with chronic kidney disease. The results of this study would identify the anti-albuminuric role of eplerenone in patients with chronic kidney disease.

Download ppt "The Evaluate Trial. Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment."

Similar presentations

The role of lercanidipine in the treatment of hypertension:

The role of lercanidipine in the treatment of hypertension:
CE REVIEW UNDERSTANDING HYPERTENSION. Hypertension is a chronic medical condition affecting more than 65 million Americans. Controlling hypertension is.

CE REVIEW UNDERSTANDING HYPERTENSION. Hypertension is a chronic medical condition affecting more than 65 million Americans. Controlling hypertension is.
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
THE IMPORTANCE OF PUBLISHING NEGATIVE FINDINGS Rolofylline, an Adenosine A1 – Receptor Antagonist, in Acute Heart Failure Barry M. Massie et al The New.

THE IMPORTANCE OF PUBLISHING NEGATIVE FINDINGS Rolofylline, an Adenosine A1 – Receptor Antagonist, in Acute Heart Failure Barry M. Massie et al The New.
Brown JR et al. Proc ASH 2013;Abstract 523.

Brown JR et al. Proc ASH 2013;Abstract 523.
ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.

ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.
Mineralocorticoid Excess Hyperaldostronism. Epidemiology first description of a patient with an aldosterone-producing adrenal adenoma (Conn's syndrome)

Mineralocorticoid Excess Hyperaldostronism. Epidemiology first description of a patient with an aldosterone-producing adrenal adenoma (Conn's syndrome)
Farxiga™ - Dapagliflozin

Farxiga™ - Dapagliflozin
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Smoking Cessation in Smokers Motivated to Quit Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Robert Anthenelli.

Smoking Cessation in Smokers Motivated to Quit Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Robert Anthenelli.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010 [Accessed.

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.

Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.

A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.

Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.

Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
6 / 5 / 2006 - 1 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Circulatory System- Hypertension Disease By: Jennifer Arroyo.

Circulatory System- Hypertension Disease By: Jennifer Arroyo.

Similar presentations

Ads by Google